OCUGEN, INC. Increase (Decrease) in Due to Related Parties, Current
OCUGEN, INC. (OCGN) reported Increase (Decrease) in Due to Related Parties, Current of -$375.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent · last filed 2019-03-22
- OCUGEN, INC. increase (decrease) in due to related parties, current for the quarter ending 2016-12-31 was $238.00K.
- OCUGEN, INC. increase (decrease) in due to related parties, current for the quarter ending 2016-09-30 was $514.00K, a 41.39% decline year-over-year.
- OCUGEN, INC. increase (decrease) in due to related parties, current for the quarter ending 2016-06-30 was $385.00K, a 65.53% decline year-over-year.
- OCUGEN, INC. increase (decrease) in due to related parties, current for the quarter ending 2016-03-31 was $357.00K, a 12.62% increase year-over-year.
- OCUGEN, INC. increase (decrease) in due to related parties, current for fiscal 2018 was -$375.00K.
- OCUGEN, INC. increase (decrease) in due to related parties, current for fiscal 2016 was $1.49M, a 2.92% decline from fiscal 2015.
- OCUGEN, INC. increase (decrease) in due to related parties, current for fiscal 2015 was $1.54M.
| Period end | Increase (Decrease) in Due to Related Parties, Current 3 month | Increase (Decrease) in Due to Related Parties, Current 6 month | Increase (Decrease) in Due to Related Parties, Current 9 month | Increase (Decrease) in Due to Related Parties, Current 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$375.00K 10-K · filed 2019-03-22 | |||
| 2016-12-31 | $238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $752.00K derived: sum of 2 quarters · filed 2018-03-15 | $1.14M derived: sum of 3 quarters · filed 2018-03-15 | $1.49M 10-K · filed 2018-03-15 |
| 2016-09-30 | $514.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $899.00K derived: sum of 2 quarters · filed 2017-11-09 | $1.26M 10-Q · filed 2017-11-09 | $484.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | $385.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $742.00K 10-Q · filed 2017-08-10 | -$30.00K derived: sum of 3 quarters · filed 2017-08-10 | $847.00K derived: sum of 4 quarters · filed 2017-08-10 |
| 2016-03-31 | $357.00K 10-Q · filed 2017-05-11 | -$415.00K derived: sum of 2 quarters · filed 2017-05-11 | $462.00K derived: sum of 3 quarters · filed 2017-05-11 | $1.58M derived: sum of 4 quarters · filed 2017-05-11 |
| 2015-12-31 | -$772.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $105.00K derived: sum of 2 quarters · filed 2017-03-16 | $1.22M derived: sum of 3 quarters · filed 2017-03-16 | $1.54M 10-K · filed 2017-03-16 |
| 2015-09-30 | $877.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.99M derived: sum of 2 quarters · filed 2016-11-10 | $2.31M 10-Q · filed 2016-11-10 | |
| 2015-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $1.43M 10-Q · filed 2016-08-11 | ||
| 2015-03-31 | $317.00K 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |